Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease

Silvia Ingala1,2 · Ingrid S. van Maurik3,4 · Daniele Altomare3,5,6 · Raphael Wurm1,7 · Ellen Dicks3 · Ronald A. van Schijndel1 · Marissa Zwan3 · Femke Bouwman3 · Niki Schoonenboom8 · Leo Boelaarts9 · Gerwin Roks10 · Rob van Marum11,12 · Barbera van Harten13 · Inge van Uden14 · Jules Claus15 · Viktor Wottschel1 · Hugo Vrenken1 · Mike P. Wattjes1,16 · Wiesje M. van der Flier3,4 · Frederik Barkhof1,17

Abstract

Objectives Neurodegeneration in suspected Alzheimer’s disease can be determined using visual rating or quantitative volumetric assessments. We examined the feasibility of volumetric measurements of gray matter (GMV) and hippocampal volume (HCV) and compared their diagnostic performance with visual rating scales in academic and non-academic memory clinics.

Materials and methods We included 231 patients attending local memory clinics (LMC) in the Netherlands and 501 of the academic Amsterdam Dementia Cohort (ADC). MRI scans were acquired using local protocols, including a T1-weighted sequence. Quantification of GMV and HCV was performed using FSL and FreeSurfer. Medial temporal atrophy and global atrophy were assessed with visual rating scales. ROC curves were derived to determine which measure discriminated best between cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer’s dementia (AD).

Results Patients attending LMC (age 70.9 ± 8.9 years; 47% females; 19% CN; 34% MCI; 47% AD) were older, had more cerebrovascular pathology, and had lower GMV and HCV compared to those of the ADC (age 64.9 ± 8.2 years; 42% females; 35% CN, 43% MCI, 22% AD). While visual ratings were feasible in > 95% of scans in both cohorts, quantification was achieved in 94–98% of ADC, but only 68–85% of LMC scans, depending on the software. Visual ratings and volumetric outcomes performed similarly in discriminating CN vs AD in both cohorts.

Conclusion In clinical settings, quantification of GM and hippocampal atrophy currently fails in up to one-third of scans, probably due to lack of standardized acquisition protocols. Diagnostic accuracy is similar for volumetric measures and visual rating scales, making the latter suited for clinical practice.

Summary statement In a real-life clinical setting, volumetric assessment of MRI scans in dementia patients may require acquisition protocol optimization and does not outperform visual rating scales.

Key Points

• In a real-life clinical setting, the diagnostic performance of visual rating scales is similar to that of automatic volumetric quantification and may be sufficient to distinguish Alzheimer’s disease groups.
• Volumetric assessment of gray matter and hippocampal volumes from MRI scans of patients attending non-academic memory clinics fails in up to 32% of cases.
• Clinical MR acquisition protocols should be optimized to improve the output of quantitative software for segmentation of Alzheimer’s disease–specific outcomes.

Keywords Alzheimer’s disease · Magnetic resonance imaging (MRI) · Hippocampal volume (HCV) · Gray matter volume (GMV) · Visual rating scales

References

© The Author(s) 2022

Extended author information available on the last page of the article
Alzheimer’s dementia (AD) is the final clinical stage of Alzheimer’s disease, a progressive neurodegenerative condition leading to neuronal loss [1]. MRI is recommended at least once in the diagnostic workup of patients attending memory clinics, as it improves diagnostic sensitivity and specificity when used in combination with other biomarkers [2–4]. Structural brain MRI provides a non-invasive and reliable way of quantitively assessing the degree of atrophy in vivo through measures of global and regional volumes that have proven valuable in identifying subjects at risk of cognitive decline even before the occurrence of dementia [1, 5]. The latest clinical and research guidelines for the definition of Alzheimer’s disease recommend to include MRI in the assessment of potentially at-risk individuals and quantify neurodegeneration [6–10].

Assessment of MRI scans in the clinical setting relies mostly on the detection of patterns of generalized or medial temporal, parietal, and global cortical atrophy in the brain [5, 11], often supported by visual rating scales [1, 2, 12]. Methods for quantification of (regional) atrophy have so far been mostly restricted to the research domain. In real-life clinical settings, successful efforts to go beyond descriptive radiological reports both in academic and non-academic real-life centers have been reported, but the widespread use of quantification methods is still hampered by lack of neuroradiologists’ training, lack of requests by the clinicians, and time issues [13].

While visual inspection using rating scales is not very demanding, this method has some degree of subjectivity and it is dependent on the rater’s experience. Conversely, quantitative methods may provide more objective and sensitive readouts, but are more time-consuming and their output might be affected by the quality of the scans [12, 14–16]. While many methods for quantification are available for research purposes, their value in the clinical setting has not been investigated yet, and they require a higher degree of standardization, being sensitive to MRI acquisition parameters [17].

We aimed to use clinical MRI scans from a mono-center, academic (retrospectively acquired) and multi-center, non-academic (prospectively collected) memory clinics within The Netherlands to establish the feasibility of quantifying atrophy in real-life clinical settings and determine whether these techniques better distinguish diagnostic groups than visual rating scales. To this end, total gray matter volume (GMV) and hippocampal volume (HCV) were quantified with two different automated pipelines and the degree of atrophy was also assessed through visual rating scales. Quality control of routinely acquired scans and the output of quantitative pipelines were performed to establish whether clinical MRI scans are suitable for such measurements. Finally, we established whether quantitative and visual measures differed in diagnostic performance in both academic and non-academic real-life clinical settings.

### Materials and methods

#### Study participants

This study used data acquired as part of the Alzheimer’s biomarkers in daily practice (ABIDE) project that focuses on the translation of knowledge on diagnostics test, including MRI, to daily clinical practice [18]. A total of 231 MRI scans from patients attending one of eight non-academic, local memory clinics (LMC) in The Netherlands [18] were prospectively collected between May 2015 and January 2017. Inclusion criteria were a Mini-Mental State Examination (MMSE) score ≥ 18 and the possibility of undergoing an MRI scan.

On the basis of clinical assessment, MRI, and performance in the neuropsychological assessment, subjects were classified as either cognitively normal (CN), with mild cognitive impairment (MCI), or with AD according to clinical criteria [9]. All subjects with a diagnosis of dementia other than AD were excluded from the study (n = 25).

The sample complemented with 492 patients retrospectively collected from Amsterdam Dementia Cohort (ADC) at the Amsterdam University Medical Center (UMC), location VUmc, with matching eligibility criteria [19], leading to a total of 698 subjects (LMC n = 206, ADC n = 492). All patients in ADC underwent a standardized clinical assessment including medical history, physical and neurological examination, laboratory tests, lumbar puncture, neuropsychological testing, and brain MRI. Clinical diagnoses were performed by a multidisciplinary team according to international guidelines [6–10].

All patients signed informed consent and the study was approved by the institutional ethical committee.
MRI data acquisition and analyses

As a part of the routine clinical visit, anatomical T1-weighted (T1w) images were acquired on clinical MRI scanners with a field strength of either 1.5 T or 3 T using a spoiled gradient-echo type of sequence (e.g., MPRAGE, FSPGR, TFE). Depending on the acquisition site, the MRI protocol also included additional sequences to visually assess vascular pathology, exclude incidental findings, and help in establishing the clinical diagnosis.

Visual reads of the complete imaging dataset were performed by an experienced neuroradiologist (M.P.W.) blinded to clinical information. Visual reads were performed in native space using established, validated semiquantitative visual rating scales (medial temporal lobe atrophy scores, MTA 0–4; posterior cortical atrophy scores, PCA 0–3; global cortical atrophy scores, GCA 0–3; Fazekas score for white matter hyperintensities of probable vascular origin, 0–3) [12, 20, 21].

For volumetric outcomes, we selected two automated, model-based approaches for segmenting T1w images, FSL (v6.0, http://www.fmrib.ox.ac.uk/fsl/) and FreeSurfer v6.0, both easy to use, well documented, and freely available. Outcomes of interest were total GMV and HCV.

Using the FSL pipeline, GMV was derived, together with a scaling factor normalizing for brain size, via structural image evaluation using normalization of atrophy (SIENAX) [22]. Similarly, HCV was calculated using FIRST [23]. Left HCV and right HCV were averaged. Both GMV and HCV were normalized for brain size using the scaling factor.

Automated cortical parcellations in FreeSurfer were run using a default script template (recon-all). FreeSurfer image analysis suite performs cortical reconstruction and volumetric segmentation of T1w images into GM, white matter, and cerebrospinal fluid [24]. Left HCV and right HCV were averaged. Normalization of FreeSurfer-derived results was performed by correcting for the mean estimated total intracranial volume.

All scans were centrally collected in the Amsterdam University Medical Center (UMC) and analyses were performed by a single operator (S.I.) blinded to clinical information using identical pipelines. The output of FSL and FreeSurfer was visually inspected for image and segmentation quality by two experienced readers blinded to clinical information (S.I. and R.W.). Scans failed QC if at least one of the following occurred: lack of the appropriate sequence for analysis, incorrect registration or segmentation, failure of the pipeline, or implausible volume estimation.

Statistical analyses

First, we compared the output of visual quality control (QC) regarding the visual reads and volumetric pipelines (FSL SIENAX, FSL FIRST, FreeSurfer) between the ADC and LMC (Fig. 1) using the Kruskal–Wallis test. After excluding results that failed QC, we proceeded to scrutinize the clinical and radiological characteristics of each diagnostic group (CN, MCI, AD) comparing results between ADC and LMC cohorts. As variables were not normally distributed, we used non-parametric tests, namely Kruskal–Wallis test for continuous variables and Mann–Whitney U tests for categorical variables.

We then focused on the measures of GMV and HCV, each assessed with visual reads (GCA for GMV, and MTA for HCV), FSL and FreeSurfer. We used Kendall’s rank correlations to examine concordance between visual reads and quantitative volumetric measures, while concordance between FSL and FreeSurfer output was examined with Pearson’s correlation.

To establish which measure better discriminates the diagnostic groups on the base of GMV and HCV, we derived receiver operating characteristic (ROC) curves for comparisons of interest, i.e., CN vs AD, and CN vs MCI. Corresponding areas under the curve (AUCs) were compared using DeLong’s test [25] for FSL vs FreeSurfer (continuous measures), while for comparison with visual reads, we used a bootstrap test for two correlated ROC curve (continuous vs ordinal categorical measures; boot number = 2000) [26].

Significance was set at \(p\) value < 0.05. All statistical analyses were performed with R, version 3.6.0 (R Foundation for Statistical Computing, https://www.r-project.org/).

Results

Study participants

Demographics, clinical, and radiological characteristics of the study participants are reported in Table 1. Overall, patients from the LMC were older than those from the ADC independent of their diagnosis. Sex ratio was roughly equally distributed among the different groups and cohorts. The diagnostic groups were distributed as follows: 214 CN (29.2%; of which 174 ADC, 40 LMC), 279 MCI (38.1% of which 209 ADC, 70 LMC), and 205 with AD dementia (28.0% of which 109 ADC, 96 LMC). As expected, MMSE decreased progressing along the AD spectrum (\(p\) value < 0.001). AD patients from LMC had significantly higher MMSE scores than AD patients from ADC.

Cerebrovascular burden, assessed with the Fazekas rating scale, was significantly higher in LMC patients in CN and AD groups, but not in MCI. GMV and HCV markers from visual ratings and volumetric pipelines showed higher degree of atrophy in the AD spectrum (\(p\) value < 0.001) in both settings.

Quantitative volumetric values of GMV were lower in subjects from LMC compared to ADC in all groups (CN, MCI, AD) after correction for age and sex, independently of the pipeline used. The same was true for HCV measures, except in the AD
groups, where no significant differences between the two different cohorts were found independent of the pipeline used (Fig. 2).

Specifically, LMC patients demonstrated significantly lower GMV and HCV values compared to ADC patients with all pipelines at all groups, except for PCA and MTA in dementia stage and FSL HCV at the MCI stage (Table 1).

**MRI quality control**

An overview of the visual QC results is shown in Fig. 1. Trends in failure rates of each pipeline followed similar patterns in the ADC and LMC. As expected, almost all scans were suitable for visual rating (failed QC for visual reads ADC = 2.2%; LMC = 1.5%). Regarding quantification, FSL was the most failure-prone, independent of the cohort (scans failing SIENAX QC: ADC = 4.1%, LMC = 32.5%; failing FIRST QC: ADC = 6.1%, LMC = 20.9%). FreeSurfer performed better with 2.2% QC failures for ADC and 15% for LMC. For all automatic pipelines, the failure rate was significantly higher in the multicenter LMC compared to mono-center, academic ADC ($p < 0.001$). A detailed description of the failure rate per site and the scanning protocols of each site are reported in Table S1 of the Supplementary Materials. While the majority of patients from the ADC

Table 1: Descriptive clinical and radiological characteristics of the cohorts. Data are reported as mean ± SD for continuous variables or n (%) for dichotomous variables. $p$ values are reported as follows: *0.05, **0.01

| Cognitive normal (CN)       | Mild cognitive impairment (MCI) | Alzheimer’s dementia (AD)   |
|-----------------------------|---------------------------------|-----------------------------|
| n                           | ADC LMC $p$ value               | ADC LMC $p$ value           | ADC LMC $p$ value               |
| Age                         | 61.4 ± 8.1                      | 66.2 ± 7.7                  | 67.7 ± 7.5                     |
| Sex, male                   | 0.61 (61.5%)                    | 0.386                       | 0.339                         |
| MMSE                        | 28.1 ± 1.6                      | 26.6 ± 2.5                  | 26.5 ± 2.5                     |
| Visual ratings              | 0.66 ± 0.66                     | 1.09 ± 0.88                 | 1.00 ± 0.82                    |
| Fazekas                     | 0.37 ± 0.54                     | 0.71 ± 0.63                 | 1.36 ± 0.69                    |
| GCA                         | 0.47 ± 0.62                     | 0.71 ± 0.65                 | 0.46 ± 0.93                    |
| PCA L/R avg                 | 0.33 ± 0.46                     | 0.76 ± 0.83                 | 1.46 ± 0.93                    |
| MTA L/R avg                 | 0.05                            | 0.104                       | 0.082                         |
| FSL Total GMV [cm$^3$]      | 769.4 ± 45.6                    | 740.9 ± 55.1                | 700.6 ± 42.8                   |
| FSL HCV L/R avg [cm$^3$]    | 2.97 ± 0.54                     | 2.70 ± 0.57                 | 2.37 ± 0.55                    |
| Scaling factor              | 1.28 ± 0.12                     | 1.28 ± 0.13                 | 1.31 ± 0.12                    |

**Fig. 1 Overview of the visual QC per pipeline and per cohort**
sample were scanned on a 3-T scanner, most of the patients from the LMC sample were scanned on 1.5-T scanners. Furthermore, in the LMC, failure rate seemed to follow a site-related pattern.

**Concordance between visual atrophy scores and quantitative MR metrics**

As expected, strong correlations were found between visual ratings, FSL, and FreeSurfer outcomes of GMV and HCV respectively (Table 2, p value < 0.001), as shown in Fig. 3. Correlation coefficients were similar for ADC and LMC. Concordance levels were higher between visual ratings and volumetric measures after normalization for head size. On the contrary, the correlation coefficient of the volumetric output of FSL and FreeSurfer for GMV and HCV was higher before normalization, due to the different normalization procedure of the two different pipelines (Table 2).

**Diagnostic performance of MRI metrics**

ROC curves distinguishing CN vs AD and CN vs MCI on the base of GMV and HCV as assessed with visual ratings, FSL, and FreeSurfer are shown in Fig. 4. AUC of the ROC curves and results of comparisons between the different methods are reported in Table 3. In line with the expected degree of neurodegeneration per group, AUCs were higher when distinguishing CN vs AD and performance decreased for CN vs MCI.

The discriminative power among groups was consistently higher in the ADC compared to LMC.

Within the LMC, FreeSurfer performed significantly better than FSL (p value = 0.038) and slightly better than MTA (p value = 0.077) in distinguishing CN vs MCI on the base of HCV (AUC_{MTA}: 0.59, 95% CI: 0.49–0.70; AUC_{FSL} 0.55, 95% CI: 0.42–0.67; AUC_{FreeSurfer}: 0.70, 95% CI: 0.59–0.81). No other significant differences in performance between visual ratings and volumetric measures were found when distinguishing clinical groups within the LMC.

Within the ADC, the best discriminative power between CN and AD was demonstrated for MTA, although AUCs for the quantitative HCV values were not significantly inferior (AUC_{MTA}: 0.85, 95% CI: 0.80–0.89; AUC_{FSL} 0.79, 95% CI: 0.73–0.75; AUC_{FreeSurfer}: 0.83, 95% CI: 0.78–0.88). For global atrophy, GCA visual rating scale and FSL volumes outperformed FreeSurfer (AUC_{GCA}: 0.84, 95% CI: 0.80–0.88; AUC_{FSL} 0.84, 95% CI: 0.80–0.88).

---

**Fig. 2** a–d Normalized HCV and GMV calculated with FSL and FreeSurfer pipelines per diagnostic group (CN, MCI, AD) and per cohort (ADC, LMC). Measures are displayed as residuals, corrected for age and sex.

---

(continued...
Table 2  Kendall’s rank correlations between visual rating scales (GCA and MTA respectively) and volumetric measures of GMV and HCV (with FSL and FreeSurfer pipelines respectively) and Pearson’s correlation between FSL and FreeSurfer measures of GMV and HCV before (bottom) and after (top) normalization for head size. All p values were < 0.001 and are indicated with **

|                  | ADC | LMC |
|------------------|-----|-----|
| **Normalized**   |     |     |
| Kendall’s rank correlations | GMV Cor. coef. (tau) | HCV Cor. coef. (tau) | GMV Cor. coef. (tau) | HCV Cor. coef. (tau) |
| Visual Rating vs FSL | -0.44 ** | -0.35 ** | -0.29 ** | -0.36 ** |
| Visual Rating vs FreeSurfer | -0.33 ** | -0.43 ** | -0.35 ** | -0.47 ** |
| Pearson’s correlation | GMV Cor. coef. (95% CI) | HCV Cor. coef. (95% CI) | GMV Cor. coef. (95% CI) | HCV Cor. coef. (95% CI) |
| FSL vs FreeSurfer | 0.74 (0.69 – 0.78) ** | 0.47 (0.40 – 0.54) ** | 0.68 (0.58 – 0.76) ** | 0.49 (0.37 – 0.61) ** |
| **Not Normalized** |     |     |
| Kendall’s rank correlations | GMV Cor. coef. (tau) | HCV Cor. coef. (tau) | GMV Cor. coef. (tau) | HCV Cor. coef. (tau) |
| Visual Rating vs FSL | -0.29 ** | -0.46 ** | -0.27 ** | -0.43 ** |
| Visual Rating vs FreeSurfer | -0.20 ** | -0.38 ** | -0.26 ** | -0.44 ** |
| Pearson’s correlation | GMV Cor. coef. (95% CI) | HCV Cor. coef. (95% CI) | GMV Cor. coef. (95% CI) | HCV Cor. coef. (95% CI) |
| FSL vs FreeSurfer | 0.94 (0.93 – 0.95) ** | 0.87 (0.84 – 0.89) ** | 0.91 (0.88 – 0.94) ** | 0.83 (0.77 – 0.87) ** |

Fig. 3  Concordance between visual reads and volumetric outcomes of GMV (a, c, e, g, i, k) and HCV (b, d, f, h, j, l). GMV was assessed through GCA visual rating, FSL SIENAX, and FreeSurfer. Similarly, HCV was assessed through MTA, FSL FIRST, and FreeSurfer. HCV were averaged between left and right (L/R) hemispheres. Volumetric outcomes (FSL and FreeSurfer) were normalized for head size and they are reported in [mm³]

Amsterdam Dementia Cohort (ADC)

Local Memory Clinics (LMC)
CI: 0.80–0.89; AUC\textsubscript{FreeSurfer}: 0.78, 95% CI: 0.73–0.84; \(p\) value GCA vs FreeSurfer: 0.047; \(p\) value FSL vs FreeSurfer: 0.018).

The results of the same analyses with non-normalized GMV and HCV data are reported in Table S2 of the Supplementary Materials.

**Discussion**

We compared the feasibility of determining gray matter and hippocampal atrophy through semi-quantitative (using visual rating scales) and quantitative (automatic software) assessments in a real-life clinical setting of local memory clinics within The Netherlands. Automated analysis failed in up to 32% of cases without protocol optimization, much more frequent than in an academic setting. We showed that visual rating scales have a lower failure rate than quantitative analyses and have a similar discriminative power to discern clinical stages of Alzheimer’s disease.

MRI biomarkers are fundamental in the assessment of patients with Alzheimer’s disease, especially at the early stages, as indicated by the strategic roadmap for early diagnosis of Alzheimer’s disease based on biomarkers [3, 4, 17]. HCV, in particular, has been shown to add specificity to the diagnosis of Alzheimer’s disease, even in the early disease stages [3, 4, 17, 27]. Our results confirm that both GMV and HCV can be used in distinguishing clinical stages along the AD spectrum, and support the clinical validity of these biomarkers, and in particular visual reads results, in light of their performance in distinguishing diagnostic groups along the Alzheimer’s continuum.

Failure rate in LMC differed based on the software used; we focused on two popular freeware solution only (FSL and FreeSurfer) and did not examine commercial software packages. In those subjects where quantification was successful, quantification did not lead to higher accuracy than visual rating by an experienced neuroradiologist. Based on our findings, the diagnostic performance of visual rating scales from an experienced reader is sufficient and generally comparable to that of volumetric outcomes, with the additional advantage of suffering less from quality issues in the images, even in non-academic settings. A possible advantage of quantification using automated pipelines is that they provide a greater level of detail, being continuous variables. Additional advantages of the use of quantitative outcomes could be to expedite the radiological assessment of MRI scans and decrease subjectivity if well integrated in the radiological flow. This could become more relevant with the continuous improvement of the segmentation techniques and the advent of artificial intelligence.

![ROC curves](image_url)

**Fig. 4** ROC curves distinguishing CN vs AD (top, a–d) and CN vs MCI (bottom, e–h) on the base of visual rating (green), FSL (red), and FreeSurfer outcomes of GMV and HCV. Results are reported separately for the Amsterdam Dementia Cohort (ADC, left panel, a, b, c, f) and local memory clinics (LMC, right panel, c, d, g, h).
intelligence and automatic decision support tools that can lead to more precise volumetric measures [28–30]. On the other hand, issues related to training and technical expertise required to produce such volumetric outputs currently prevent a practical implantation in the clinics.

The images we used for volumetric quantifications came from real-life clinical settings, and were thus variable in terms of scanners, acquisition protocol parameters, and general quality. Our results suggest that the quality of ADC MRI scans was generally higher when compared to LMC. This might partially reflect efforts to achieve protocol standardization across scanners within the ADC [19] and different levels of experience between academic and non-academic centers. Moreover, most of the data from the ADC as acquired with 3T scanners, as opposed to the LMC where most data were collected on 1.5-T scanners. This has probably impacted the number of failures and the quality of the segmentations in favor of the ADC. We reported scanning protocol details in the Supplementary Materials. Although the disentangling of technical scanning parameters that could affect volumetric measurement with automatic software goes beyond the scope of this study, research in this direction would certainly aid in the translation of automatic software use in the clinical practice. Finally, data collection also differed between the academic and non-academic centers, as the LMC sample was prospectively collected, while the ADC sample was retrospectively included in the analyses as the data were already available.

Moreover, the two samples had different clinical characteristics, as patients referred to academic centers are usually clinically more challenging, while older patients with a less complex diagnostic profile were investigated at LMC. This is confirmed by the significant differences between the ADC and LMC samples in age, MMSE score, vascular burden, and respective numbers of diagnostic groups, as patients from LMC generally presented in more advanced stages of disease (MCI, dementia), although MMSE values within the dementia stage were higher in the LMC group, suggesting that this screening test does not capture clinical nuances. In line with this hypothesis, the GMV and HCV were consistently lower in individuals from LMC in all syndromic groups, independently of the pipeline used. This might have also influenced the diagnostic performance within LMC, as the volumetric assessment of atrophic brains is more challenging, due to increased segmentation uncertainty as a function of the ratio between the surface area and the volume of the structure [31].

The use of real-life clinical data both from academic and non-academic memory clinics is a strength of this study, making results applicable to a clinical setting. Although follow-up data were not available for this study, it has been previously demonstrated that volumetric measures are more sensitive to change than visual reads. On the other hand, these measures

---

**Table 3** Ability of visual reads, FSL, and FreeSurfer (FS) to distinguish CN vs AD and CN vs MCI based on GMV and HCV outcomes. Area under the curve (AUC) of ROC curves is reported with 95% confidence interval. *p values are obtained through DeLong’s method when comparing FSL vs FS and with bootstrap test for two correlated ROC curves when comparing visual reads against FSL or FS (boot number = 2000).

| Normalized GMV | ADC GCA AUC (95% CI) | FSL AUC (95% CI) | FreeSurfer (FS) AUC (95% CI) | GCA vs FSL p-value | GCA vs FS p-value | FSL vs FS p-value |
|---------------|----------------------|------------------|-------------------------------|---------------------|------------------|-------------------|
| CN vs AD      | 0.84 (0.80 – 0.88)    | 0.84 (0.80 – 0.89)| 0.78 (0.73 – 0.84)           | 0.656               | *0.047           | *0.018            |
| CN vs MCI     | 0.64 (0.59 – 0.69)    | 0.63 (0.57 – 0.69)| 0.64 (0.58 – 0.69)           | 0.488               | 0.758            | 0.888             |

| LMC GCA AUC (95% CI) | FSL AUC (95% CI) | FreeSurfer (FS) AUC (95% CI) | GCA vs FSL p-value | GCA vs FS p-value | FSL vs FS p-value |
|---------------------|------------------|-------------------------------|---------------------|------------------|-------------------|
| CN vs AD            | 0.66 (0.57 – 0.76)| 0.78 (0.67 – 0.89)           | 0.69 (0.58 – 0.81)  | 0.210            | 0.791             | 0.078             |
| CN vs MCI           | 0.63 (0.52 – 0.73)| 0.66 (0.53 – 0.79)           | 0.67 (0.55 – 0.79)  | 0.486            | 0.900             | 0.683             |

| Normalized HCV | ADC MTA AUC (95% CI) | FSL AUC (95% CI) | FreeSurfer (FS) AUC (95% CI) | MTA vs FSL p-value | MTA vs FS p-value | FSL vs FS p-value |
|---------------|----------------------|------------------|-------------------------------|---------------------|------------------|-------------------|
| CN vs AD      | 0.85 (0.80 – 0.89)    | 0.79 (0.73 – 0.85)| 0.83 (0.78 – 0.88)           | 0.099               | 0.636            | 0.217             |
| CN vs MCI     | 0.65 (0.60 – 0.70)    | 0.64 (0.59 – 0.70)| 0.69 (0.63 – 0.74)           | 0.792               | 0.255            | 0.163             |

| LMC MTA AUC (95% CI) | FSL AUC (95% CI) | FreeSurfer (FS) AUC (95% CI) | MTA vs FSL p-value | MTA vs FS p-value | FSL vs FS p-value |
|---------------------|------------------|-------------------------------|---------------------|------------------|-------------------|
| CN vs AD            | 0.70 (0.61 – 0.80)| 0.73 (0.62 – 0.85)           | 0.79 (0.70 – 0.88)  | 0.410            | 0.084             | 0.646             |
| CN vs MCI           | 0.59 (0.49 – 0.70)| 0.56 (0.42 – 0.67)           | **0.70 (0.59 – 0.81)** | 0.077            | 0.075            | *0.038            |
are also susceptible to changes as a consequence of variations in scanning protocols and technical parameters, which might also be a pitfall. A limitation of this study is that we did not study visual reads by local (neuro)radiologist; likewise, the volumetric quantification and QC were performed centrally. This is also a strength, as variability was limited, making our results more robust. We only used two popular freeware solutions (FSL and FreeSurfer) for quantification of GMV and HCV. Although a comprehensive comparison of all possible methods for GMV and HCV quantification methods and the investigation of their technical peculiarities was beyond the scope of this study, these methodological differences, coupled with our consequent choices (for instance in normalization for head size), might have introduced a bias in the results, as no consensus exists regarding the correct way to analyze volumetric data. Finally, results might have improved with quality assessment of intermediate analysis steps. Nevertheless, we aimed at reproducing as much as possible what could happen in a real-life clinical setting where time and resources limit the feasibility of step-by-step QC of standardized pipelines.

In conclusion, our results indicate that brain MRI scans from non-academic memory clinics have a considerable failure rate for the quantification of GMV and HCV without protocol optimization. Quantitative volumetric outputs of automatized software were generally not superior to visual ratings by an experienced radiologist, suggesting that, given the time constraints and limited resources of real-life clinical settings, the use of such software may not yet be ready for use in the radiological workup of individuals with suspected Alzheimer’s disease. Although their implementation in the clinical world remains still complex, quantitative measures remain promising tools to standardize the ratings, save time to manual operators, and give more precise quantifications of brain atrophy.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00330-021-08503-7.

Acknowledgements The authors would like to acknowledge all the patients that have donated their data and the personnel that contributed to the data collection, as this research would not have been possible without their time and dedication. Moreover, we would like to thank Bertjan Kerklaan, Henry Weinstein, and Jooske Boomsma for their contribution to this study.

ABIDE study group: Amsterdam, The Netherlands (Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center): Wiejsje M. van der Flier, PhD, Peter van Walderveen, MD (Medisch Centrum Leeuwarden, Leeuwarden); Ester Korf, MD, PhD (Admiraal de Ruyter Ziekenhuis, Vlissingen); Gerwin Roks, MD, PhD (Sint Elisabeth Ziekenhuis, Tilburg); Bertjan Kerklaan, MD, PhD (Onze Lieve Vrouwe Goudswaard, Amsterdam); Leo Boelaarts, MD (Medisch Centrum Alkmaar, Alkmaar); Annemieke van de Wetering, MD (Diaconessenhuis, Leiden); Rob J. van Marum, MD, PhD (Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch); Jules J. Claus, MD, PhD (Tergooi Ziekenhuis, Hilversum); Koos Keizer, MD, PhD (Catharina Ziekenhuis, Eindhoven).

Funding Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUMc fonds. WF is recipient of ZonMW Memorabel (ABIDE; project no. 733050201), a project in the context of the Dutch Deltaplan Dementie. This project has received support from the following EU/EFPIA Innovative Medicines Initiatives Joint Undertakings: EPAD grant no. 115736 (European Prevention of Alzheimer’s Dementia Consortium). WvdF and FB are recipients of a JPND grant for E-DADS (project number 733051106). FB was supported by the NIHR Biomedical Research Centre at UCLH.

Declarations

Guarantor The scientific guarantor of this publication is Prof. Dr. Frederik Barkhof.

Conflict of interest Prof. Frederik Barkhof received payment and honoraria from Bayer, Biogen, TEVA, Merck-Serono, Novartis, Roche, IXICO Ltd, GeNeuro, and Combinostics for consulting; research support or grants from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (AMYPAD consortium), EuroPOND (H2020), UK MS Society, Dutch MS Society, PICTURE, (IMDI NWO), NIHR UCLH Biomedical Research Centre (BRC), ECTRIMS-MAGNIMS.

Research programs of Prof. Wiejsje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health-Holland, Toppsector Life Sciences & Health, stichting Diophane, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding is paid to her institution. Other authors declare that they have no competing interests.

Statistics and biometry No complex statistical methods were necessary for this paper.
J. Alzheimers Dis 62:1091–1111.

Methodology

• This is a multicentric cross-sectional study
• Data from LMC were collected prospectively
• Data from ADC were collected retrospectively.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. ten Kate M, Ingala S, Schwarz AJ et al (2018) Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers Res Ther 10:112. https://doi.org/10.1186/s13195-018-0438-z
2. Scheltens P, Fox N, Barkhof F, De Carli C (2002) Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1:13–21
3. Van Maurik IS, Zwan MD, Tijms BM et al (2017) Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) project. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.2712
4. van Maurik IS, Vos SJ, Bos I et al (2019) Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol 18:1034–1044. https://doi.org/10.1016/S1474-4422(19)30283-2
5. Kinnunen KM, Cash DM, Poole T et al (2018) Presymptomatic atrophy in autosomal dominant Alzheimer’s disease: a serial magnetic resonance imaging study. Alzheimers Dement 14:43–53. https://doi.org/10.1016/j.jalz.2017.06.2268
6. Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746
7. Frisoni GB, Jack CR, Bocchetta M et al (2015) The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement 11:111–125. https://doi.org/10.1016/j.jalz.2014.05.1756
8. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279. https://doi.org/10.1016/j.jalz.2011.03.008
9. Jack CR, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:257–262. https://doi.org/10.1016/j.jalz.2011.03.004
10. Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimers disease. Alzheimers Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018
11. Van Der Flier WM, Scheltens P (2018) Amsterdam Dementia Cohort: performing research to optimize care. J Alzheimers Dis 62:1091–1111.
12. Koedam ELGE, Lehmann M, Van Der Flier WM et al (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21:2618–2625. https://doi.org/10.1007/s00330-011-2055-4
13. Vernooij MW, Pizzini FB, Schmidt R et al (2019) Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. Neuroradiology 61:633–642. https://doi.org/10.1007/s00234-019-02188-y
14. Scheltens P, Launer LJ, Barkhof F et al (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 242:557–560
15. Frisoni GB, Fox NC, Jack CR et al (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6:67–77. https://doi.org/10.1038/nrneurol.2009.215
16. Rhodus-Meester HFM, Benedictus MR, Wattjes MP et al (2017) MRI visual ratings of brain atrophy and white matter hyperintensities across the spectrum of cognitive decline are differently affected by age and diagnosis. Front Aging Neurosci 9:1–12. https://doi.org/10.3389/fnagi.2017.00017
17. Frisoni GB, Boccardi M, Barkhof F et al (2017) Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol 16:661–676. https://doi.org/10.1016/S1474-4422(17)30159-X
18. de Wilde A, van Maurik IS, Kunneman M et al (2017) Alzheimer’s biomarkers in daily practice (ABIDE) project: rationale and design. Alzheimers Dement Diagnosis, Assess Dis Monit 6:143–151. https://doi.org/10.1016/j.dadm.2017.01.003
19. van der Flier WM, Pijnenburg YAL, Prins N et al (2014) Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis 41:313–327. https://doi.org/10.3233/JAD-132306
20. Scheltens P, Leys D, Barkhof F et al (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55:967–972. https://doi.org/10.1136/jnnp.55.10.967
21. Pasquier F, Leys D, Weerts JG et al (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36:268–272. https://doi.org/10.1159/000117270
22. Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489. https://doi.org/10.1006/nimg.2002.1040
23. Patenaude B, Smith SM, Kennedy DN, Jenkinson M (2011) A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 56:907–922. https://doi.org/10.1016/j.neuroimage.2011.02.046
24. Dale AM, Fischl B, Sereno MI (1991) Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 27:65–84
25. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
26. Liu H, Li G, Cumberland WG, Wu T (2005) Testing statistical significance of the area under a receiving operating characteristics curve for repeated measures design with bootstrapping. J Data Sci 3:257–278. https://doi.org/10.6339/JDS.2005.03(3).206
27. Visser P, Verhey F, Hofman P et al (2002) Medial temporal lobe atrophy predicts Alzheimer’s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 72:491. https://doi.org/10.1136/JNNP.72.4.491
28. Goodkin O, Pemberton H, Vos SB et al (2019) The quantitative neuroradiology initiative framework: application to dementia. Br J Radiol 92:20190365. https://doi.org/10.1259/bjr.20190365
29. Koikkalainen JR, Rhodius-Meester HFM, Frederiksen KS et al (2019) Automatically computed rating scales from MRI for patients with cognitive disorders. Eur Radiol 29:4937–4947. https://doi.org/10.1007/s00330-019-06067-1
30. Lötjönen J, Wolz R, Koikkalainen J et al (2011) Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer’s disease. Neuroimage 56:185–196. https://doi.org/10.1016/j.neuroimage.2011.01.062
31. Cash DM, Frost C, Iheme LO et al (2015) Assessing atrophy measurement techniques in dementia: results from the MIRIAD atrophy challenge. Neuroimage 123:149–164. https://doi.org/10.1016/j.neuroimage.2015.07.087

Affiliations

Silvia Ingala1,2, Ingrid S. van Maurik3,4, Daniele Altomare3,5,6, Raphael Wurm1,7, Ellen Dicks3, Ronald A. van Schijndel1, Marissa Zwan3, Femke Bouwman3, Niki Schoonenboom8, Leo Boelaarts9, Gerwin Roks10, Rob van Marum11,12, Barbera van Harten13, Inge van Uden14, Jules Claus15, Viktor Wottschel1, Hugo Vrenken1, Mike P. Wattjes1,16, Wiesje M. van der Flier3,4, Frederik Barkhof1,17

1 Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Location VUmc, PO Box 7057, 1007 MB Amsterdam, The Netherlands
2 Department of Radiology and Nuclear Medicine, Noordwest Hospital Group, Alkmaar, The Netherlands
3 Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
4 Department of Epidemiology and Data Science, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
5 Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland
6 Memory Clinic, University Hospitals of Geneva, Geneva, Switzerland
7 Department of Neurology, Medical University of Vienna, Vienna, Austria
8 Geriatric Department, Noordwest Ziekenhuis Groep, Alkmaar, The Netherlands
9 Geriatric Department, Noordwest Ziekenhuis Groep, Alkmaar, The Netherlands
10 Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands
11 Department of Geriatrics, Jeroen Bosch Hospital, ‘S-Hertogenbosch, The Netherlands
12 Department of Family Medicine and Elderly Care Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
13 Department of Neurology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
14 Department of Neurology, Catharina Hospital, Eindhoven, The Netherlands
15 Department of Neurology, Tergooi Hospital, Blaricum, The Netherlands
16 Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany
17 Institutes of Neurology and Healthcare Engineering, UCL, London, UK